Loading…

Liver Fibrosis in Primary Sjögren’s Syndrome

BackgroundPrimary Sjögren syndrome (pSS) is a systemic autoimmune epithelitis, potentially affecting salivary epithelium, biliary epithelium, and hepatocytes. Common immunological mechanisms might cause clinically silent liver inflammation, and combined with non-alcoholic fatty liver disease (NAFLD)...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2022-06, Vol.13, p.889021-889021
Main Authors: Androutsakos, Theodoros, Voulgaris, Theodoros A., Bakasis, Athanasios-Dimitrios, Koutsompina, Maria-Loukia, Chatzis, Loukas, Argyropoulou, Ourania D., Pezoulas, Vasilis, Fotiadis, Dimitrios I., Papatheodoridis, George, Tzioufas, Athanasios G., Goules, Andreas V.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundPrimary Sjögren syndrome (pSS) is a systemic autoimmune epithelitis, potentially affecting salivary epithelium, biliary epithelium, and hepatocytes. Common immunological mechanisms might cause clinically silent liver inflammation, and combined with non-alcoholic fatty liver disease (NAFLD), liver fibrosis (LF) may occur. No studies have explored the occurrence of LF in the context of NAFLD among pSS patients. MethodsConsecutive pSS patients from the rheumatology outpatient clinic of the Department of Pathophysiology and individuals evaluated in the hepatology outpatient clinic for possible NAFLD serving as comparators underwent transient elastography (TE) to assess LF and liver steatosis (LS). All participants had no overt chronic liver disease. Clinical, demographic, and laboratory data were collected from all participants at the time of TE. ResultsFifty-two pSS patients and 198 comparators were included in the study. The median age (range) of pSS and comparators was 62.5 (30-81) and 55 (19-86) years, respectively. Both groups had similar prevalence regarding type 2 diabetes mellitus, hyperlipidemia, and similar body mass index (BMI). Patients with pSS had less frequently high LS (S2, S3) (27% vs. 62%, p < 0.001) and significant LF (F2-4) [2 (3.8%) vs. 34 (17.2%), p = 0.014] than comparators. Univariable analysis showed that advanced LF was significantly associated with older age, higher LS, greater BMI, and disease status (comparators than pSS); of these, only age was identified as an independent LF risk factor in the multivariable logistic regression analysis. ConclusionLiver fibrosis among pSS patients is most likely not attributed to the disease per se.
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2022.889021